Introduction {#s1}
============

Crystalline silica (CS) dust exposure is a common feature of sand or rock mining. Construction and ceramics production workers are also largely exposed to CS. Indeed, silica is a major component of Earth composition ([@B1]). Recently, workers in fashion industry (sand blasting) have also been recognized as highly exposed to CS. A major burden of silica exposure is silicosis ([@B2]), which is, with asbestosis, among the most frequent pneumoconiosis. This occupational lung disease presents as a progressive lung fibrosis characterized by parenchymal inflammation and nodular lesions. The pathophysiology of silicosis has been largely studied. Schematically, after phagocytosis of inhaled silica by alveolar macrophages, inflammasome activation leads to pro-inflammatory cytokines release. Macrophages, which are unable to destruct silica, undergo apoptosis; silica is then released and triggers another cycle of phagocytosis and inflammation. This chronic inflammation leads to excessive collagen production by fibroblast, leading to fibrosis ([@B2]).

Since the beginning of the last century, increased prevalence of autoimmune diseases (AID) has been observed in subjects exposed to silica, whether they suffer from silicosis or not. Rheumatoid arthritis (RA) ([@B3], [@B4]), systemic sclerosis (SSc) ([@B5]), systemic lupus erythematosus (SLE) ([@B6]--[@B9]) and ANCA-associated vasculitis (AAV) ([@B10]--[@B12]) represent the main AID which are over-represented in silica-exposed workers. The pathophysiology of these diseases in the context of silica exposure is far from being well understood and relies largely on data acquired in silicotic patients.

Several studies reported the presence of peripheral lymphopenia in silicotic patients with or without AID ([@B13], [@B14]). We hypothesized in the present study that the lymphopenia may impact preferentially regulatory T cells (Tregs) and could account for auto-immunity development. Thus, as observed in other diseases, decreased Tregs could be followed by a break of tolerance against self-antigens and could be responsible for the occurrence of AID.

To better understand early immune mechanisms, we studied a cohort of 63 silicosis-free subjects, exposed to CS, age- and sex- matched with healthy donors (HC). We analyzed the phenotype of their leucocyte by flow cytometry and screened serum markers of autoimmunity. We hereby demonstrate that, compared to HC, CS exposed workers have decreased Tregs frequency and increased T cell activation status. Moreover, CS exposed workers showed a higher frequency of ANA and ANCA positivity, reflecting B cell activation.

Materials and Methods {#s2}
=====================

Study Design, Patients, and Sample Collection
---------------------------------------------

This prospective study was conducted from January 2008 to July 2009. Silica-exposed workers were enrolled according to the following inclusion criteria: male aged between 30 and 60 years-old without history of pulmonary or rheumatic disease, exposed to CS in one of the companies included in the study, as described below. Exclusion criteria were age below 30 or above 60, female gender, past medical history of lung disease (tuberculosis, COPD, lung cancer), infectious disease or immunosuppressive regimen at the time of the study inclusion, auto-immune disease, radiologic abnormality suggestive of silicosis, asbestosis, anthracosis, or tuberculosis. Blood from age- and sex-matched HC was obtained from human volunteers (Blood collection center, Angers, France; Agreement PLER ANG 2017-01).

Companies with a common medical supervision and with available metrological data on the exposure of employees to free silica were selected. For this, the COLCHIC database from the "Institut National de Recherche et Sécurité" ([@B15], [@B16]) and files from the "Caisse d\'Assurance Retraite et de la Santé au Travail" and the "Laboratoire Interrégional de Chimie de l\'Ouest" were used. Free-silica exposure was ranked as "low," "moderate" or "high" in respect to CS exposure and according to the metrological data from the COLCHIC database: sampling used an air sampler that captures the respirable (alveolar) fraction of airborne particles (European Standard CN 481). Average exposures above 70% of the mean exposure value (MEV), or above the MEV are considered "high," exposures between 30 and 70% of the MEV are considered "moderate" and those \<30% of the MEV are considered "low" ([@B17]). Workers with moderate to high exposure were eligible for inclusion in the present study. After information about the study, randomly drawn exposed subjects who agreed to participate underwent clinical examination, chest X-ray, pulmonary function test and blood sampling.

This study followed the recommendations of the Helsinki Declaration and was approved by the ethical committee of the Angers University Hospital (CCPPRB 2006/23 and 2006/23 bis).

Autoantibody Detection
----------------------

Autoantibodies were detected in the serums of workers exposed to SC and in HC. ANA were detected by indirect immunofluorescence (IIF) on HEp2 cells (Bio-Rad) ([@B18]). Given the age of workers exposed to CS, ANA were considered positives when the dilution titer was ≥1/200th. ANCA were detected by IIF on ethanol fixed normal human neutrophils, starting the screening at a dilution of 1/20th, and were classified as cytoplasmic (cANCA), perinuclear (pANCA) or atypical (aANCA) ([@B19]). In case of IIF positivity, antimyeloperoxidase (MPO) and antiproteinase 3 (PR3) antibodies were detected using ELISA (all from Euroimmun). Rheumatoid factors (RF) were measured in serum by nephelometry and anti-citrullinated protein antibodies (ACPA) were detected by fluoroenzymology (Bio-Rad). Complete blood count was obtained from total blood on a routine automated hematology analyzer.

Flow Cytometry Analysis
-----------------------

Peripheral blood mononuclear cells (PBMC) were isolated from CS exposed workers and HC using standard density-gradient centrifugation on Lymphocyte Separation Medium (Eurobio). 10^6^ cells were incubated with antibodies listed in [Supplemental Table 1](#SM3){ref-type="supplementary-material"} (30 min, 4°C). For Tregs, after fixation and permeabilization (Intracellular Fixation & Permeabilization Buffer Set, eBioscience), cells were incubated for 30 min with anti-FoxP3 antibody. As commonly accepted, Tregs were defined as CD4^+^CD25^+^CD127^−/low^FoxP3^+^ cells ([Figure 1A](#F1){ref-type="fig"}) ([@B20]). For T cell activation assessment, 100 μL of total blood from EDTA tube was incubated (15 min, room temperature) with indicated antibodies ([Supplemental Table 1](#SM3){ref-type="supplementary-material"}). Red blood cells were lysed before flow cytometry analysis. Activated T cells were defined as CD3^+^HLA-DR^+^, CD3^+^CD4^+^HLA-DR^+^ and CD3^+^CD8^+^HLA-DR^+^ cells ([Figure 2A](#F2){ref-type="fig"}) ([@B21], [@B22]).

![Percentage of regulatory T cell is lower in exposed subjects and decreased with longer CS exposure. **(A)** Gating strategies for regulatory T cells (Tregs), as described in Santegoets et al. ([@B20]): lymphocytes were identified based on their morphology characteristics, as shown in the forward scatter (FSC) and side scatter (SSC) plot. Among these cells, the following populations were successively gated in to identify Tregs: CD3^+^ cells, CD4^+^ cells, CD25^+^CD127^−/low^, and FoxP3^+^ cells. Percentage of Tregs among CD4^+^ cells of subjects exposed or not to silica (**B**, left) or in subgroups of subjects exposed to silica (**B**, right). Total counts of circulating Tregs in subjects exposed or not to silica (**C**, left) or in subgroups of subjects exposed to CS (**C**, right). Data are shown as boxplot. *P*-values represent Mann & Whitney test for two groups comparison and, Kruskal-Wallis test for four groups comparison (if previous test significant), followed by *post-hoc* Dunn test when applicable (results indicated by asterisks, \*). *P*-values have been adjusted according to Hochberg method to account for repeated analysis. NA, not applicable.](fimmu-10-02743-g0001){#F1}

![Frequency of activated T cells is increased in CS exposed workers as compared to HC and increases with exposure length. **(A)** Gating strategies for activated T cells. Lymphocytes were identified based on their morphology characteristics \[forward scatter (FSC) and side scatter (SSC) plot\]. Among these cells, total CD3^+^ T cells were identified as well as CD4^+^ and CD8+ subsets. Activated cells were defined according to HLA-DR expression. Percentages of HLA-DR^+^ in CD3^+^, CD4^+^, or CD8^+^ cells in subjects exposed or not to CS (**B**, left) or in subgroups of subjects exposed to CS (**B**, right). Total counts of activated HLA-DR^+^ CD3^+^, CD4^+^, or CD8^+^ T cells in subjects exposed or not to silica (**C**, left) or in subgroups of subjects exposed to silica (**C**, right). Data are shown as boxplot. *P*-values represent Mann & Whitney test for two groups comparison and, Kruskal-Wallis test for four groups comparison (if previous test significant), followed by *post-hoc* Dunn test when applicable (results indicated by asterisks, \*). *P*-values have been adjusted according to Hochberg method to account for repeated analysis. NA, not applicable.](fimmu-10-02743-g0002){#F2}

Isotype antibodies or unstained cells were used as negative controls for gating strategies. Cells were immediately read with cytometer (FACSCanto II, BD Bioscience) and spectral overlap was compensated within DIVA software (BD Bioscience) before acquisition. Events were analyzed with FlowJo v10.3 software (BD Bioscience).

Statistical Analyses
--------------------

Subjects\' characteristics are reported as numbers and percentages for qualitative variables, and with mean ± standard deviation, or median \[Inter-Quartile Range (IQR)\], when appropriated, for continuous variables. Data were compared using the Fisher exact test for categorical variables or Student *t*-test or ANOVA (followed by Tukey *post-hoc* test for multiples comparisons) for normal continuous variables. For non-normal continuous variables, Mann-Whitney or Kruskal-Wallis tests (followed by Dunn *post-hoc* test for multiples comparisons when applicable) were used. For multiple comparisons, *P*-values were adjusted using the Hochberg procedure, which allows a control of the Family-wise Error Rate at 5% ([@B23], [@B24]). For flow cytometry analysis and total blood count analysis, Mann Whitney U test was followed by Kruskal-Wallis test only if *p*-value was significant. *P*-values have been adjusted according to Hochberg method to account for repeated analysis.

Data are shown as boxplot (median ± interquartile range). Vertical bar represents minimum and maximum values. Statistical analysis was performed using the R software version 3.6. *P*-values \<0.05 were considered significant (^\*^ = *p* \< 0.05, ^\*\*^ = *p* \< 0.01, ^\*\*\*^ = *p* \< 0.001).

Results {#s3}
=======

Population Characteristics
--------------------------

Complete data were available for 58 of 63 subject exposed to CS. Three additional subjects were excluded because of unexplained hyperleukocytosis (*n* = 1), hyperlymphocytosis (*n* = 1) or recent silicosis diagnosis (*n* = 1). Thus, 55 subjects were analyzed and were distributed as follows: subjects exposed to CS for \<5 years (*n* = 10), for 5--10 years (*n* = 18), and for more than 10 years (*n* = 27). They were compared to age- and sex-matched healthy control (HC). Due to limitations in the total amount of drawable blood, two cohort of HC were constituted: *n* = 42 for hematological and flow cytometry analysis (HC group 1) and *n* = 45 for autoantibody analysis (HC group 2). The flow chart of the study is reported in [Supplemental Figure 1](#SM1){ref-type="supplementary-material"}.

All included subjects were males and worked in construction companies (daily activities reported in [Supplemental Table 2](#SM4){ref-type="supplementary-material"}). There was no difference in age between the exposed group or subgroups and HC group 1 or HC group 2 ([Table 1](#T1){ref-type="table"}). Most of exposed workers wore personal protective equipments (96.4%). There was a high proportion of smokers in each exposed subgroup (58.2% overall). Smokers were more common in the subgroup of subjects exposed 5--10 years (14/18; 78%). Alcohol consumption was significantly increased in subjects exposed more than 10 years (8/27; 29.7%) ([Table 1](#T1){ref-type="table"}).

###### 

Demographical data.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                               **Non-exposed control group**   **All exposed subjects**\   **Exposed**\     **Exposed**\                               **Exposed**\                                 ***p*-values**
                                                               **(*n* = 55)**              **\<5 years**\   **5--10 years**\                           **\>10 years**\                              
                                                                                           **(*n* = 10)**   **(*n* = 18)**                             **(*n* = 27)**                               
  ---------------------------- ------------------------------- --------------------------- ---------------- ------------------------------------------ -------------------------------------------- ------------------------------------
  Sex ratio (♂/♀)              1/0                             1/0                         1/0              1/0                                        1/0                                          --

  Age (years)                  Control group 1:\               41.30 ± 6.52                38.23 ± 6.43     38.87 ± 6.18                               44.07 ± 5.91                                 NS[^‡^](#TN1){ref-type="table-fn"}
                               (*n* = 42)\                                                                                                                                                          
                               41.67 ± 12.59\                                                                                                                                                       
                               Control group 2:\                                                                                                                                                    
                               (*n* = 45)\                                                                                                                                                          
                               42.06 ± 8.89                                                                                                                                                         

  PPE                          --                              53 (96.4%)                  10 (100%)        18 (100%)                                  25 (92.6%)                                   0.67

  BMI (kg/m^2^)                --                              26.10 ± 4.56                24.55 ± 3.52     26.45 ± 5.38                               26.44 ± 4.22                                 0.49

  Smokers\                     --\                             32 (58.2%)\                 3 (30%)\         14 (78%)\                                  15 (55.6%)\                                  **0.05**\
  Active\                      --\                             22 (68.6%)\                 3 (100%)\        8 (57%)\                                   11 (73.3%)\                                  0.87\
  Past                         --                              11 (34.4%)                  0 (0%)           6 (43%)                                    4 (26.7%)                                    0.08

  Alcohol consumption          --                              9 (16.4%)                   0 (0%)           1 (5.6%)                                   8 (29.7%)                                    **0.05**

  Current medication                                                                                                                                                                                

  Occasional NSAID\            --\                             2 (3.6%)\                   1 (10%)\         --\                                        1 (3.7%)\                                    0.43\
  Anti-hypertensive\           --\                             4 (7.3%)\                   --\              1 (5.6%)\                                  3 (11.1%)\                                   0.66\
  Anti-diabetic\               --\                             1 (1.8%)\                   --\              1 (5.6%)\                                  --\                                          0.51\
  Hypolipemic\                 --\                             2 (3.6%)\                   --\              1 (5.6%)\                                  1 (3.7%)\                                    1.00\
  Bronchodilator               --                              2 (3.6%)                    1 (10%)          1 (5.6%)                                   --                                           0.24

  Abnormal chest radiography   --                              2 (7.4%)                    0 (0%)           0 (0%)                                     2 (7.4%)[^\$^](#TN2){ref-type="table-fn"}    0.70

  Abnormal PFT                 --                              5 (9.1%)                    0 (0%)           1 (5.8%)[^€^](#TN3){ref-type="table-fn"}   4 (14.8%)[^€€^](#TN4){ref-type="table-fn"}   0.58
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*The bold value indicates that ≤ 0.05*.

*p-values are from Fisher exact test otherwise specified*.

*Exposed subjects vs. control group 1 (flow cytometry analysis): p-value = 0.85 (T-test) and 0.22 (ANOVA). Exposed subjects vs. control group 2 (immunological analysis): p-value = 0.63 (T-test) and 0.07 (ANOVA)*.

*One subject with right subaxillary pleural thickening and one patient with increased peribronchial interstitium without interstitial syndrome*.

*One restrictive syndrome*.

*Three obstructive syndromes, one NA*.

*CS, crystalline silica; PPE, personal protective equipment; BMI, body mass index; NS, not significant; NSAID, non-steroidal anti-inflammatory drugs; PFT, pulmonary function test*.

Hematological Data
------------------

Complete blood count results are detailed in [Supplemental Table 3](#SM5){ref-type="supplementary-material"}. We found a slight but significant increase of hemoglobin level in subject exposed to CS, especially in the two subgroups with longer CS exposure, as compared to HC. There was a significant increase in total leucocytes and in total lymphocytes counts in subjects exposed to CS, especially in the subgroup exposed 5--10 years. We also noted a significant increase in total monocyte count in each subgroup compared to HC. Nevertheless, all these values remained within the normal range. CD3^+^ cells, including its CD4^+^ and CD8^+^ T cell subsets, and NK cell counts were significantly higher in subjects exposed to CS as compared to HC. Finally, we also observed a significant decrease of the total B cell count in each subgroup of CS-exposed subjects compared to HC. We did not find any difference between groups fort platelets, neutrophils, eosinophils and basophils counts.

Reduction of Tregs Frequency With Duration of Silica Exposure
-------------------------------------------------------------

Circulating levels of Tregs have been reported decreased in several AID ([@B25]--[@B32]). We observed a significant decrease in the percentage of Tregs in subjects exposed to CS vs. HC ([Figure 1B](#F1){ref-type="fig"}, left panel) (5.55% \[4.61--6.72\] vs. 6.81% \[5.54--8.06\], *p* = 0.02). When comparing percentages of Tregs among CS exposed workers, we observed that it significantly decreased between subgroups according to length of CS exposure ([Figure 1B](#F1){ref-type="fig"}, right panel) (6.81% \[5.54--8.06\] vs. 6.03% \[5.08--6.97\], 5.88% \[4.57--7.35\], 5.38% \[4.61--6.56\] in not exposed, exposed \<5 years, exposed 5--10 years, exposed \>10 years, respectively; *p* = 0.046). We did not find any difference between groups when considering total Tregs counts ([Figure 1C](#F1){ref-type="fig"}).

Activated T Cells Increase in Workers With the Length of Silica Exposure
------------------------------------------------------------------------

Because silica has been reported to behave as a super antigen ([@B33]), we next evaluated the expression of the activation marker ([@B21], [@B22]) HLA-DR CD3^+^, CD4^+^, and CD8^+^ T cells ([Figure 2A](#F2){ref-type="fig"}). Complete data are reported in [Supplemental Table 4](#SM6){ref-type="supplementary-material"}.

Among CD3^+^ T cells, we observed a trend to an increase in the percentage of HLA-DR-expressing cells in CS exposed workers (*p* = 0.09, [Figure 2B](#F2){ref-type="fig"}, left panel) and with length of exposure ([Figure 2B](#F2){ref-type="fig"}, right panel). There was a significant increase of the total count of activated circulating CD3^+^ T cells (128.41 cells/μL \[94.6--182.75\] vs. 72.28 cells/μL \[56.39--96.32\] in HC, *p* = 0.0002, [Figure 2C](#F2){ref-type="fig"}, left panel). This increase was mainly observed in the subgroups of subjects exposed 5--10 years (*p* = 0.001) or more than 10 years (*p* = 0.006, [Figure 2C](#F2){ref-type="fig"}, right panel).

Similar observations were made when analyzing HLA-DR expression among CD3^+^CD4^+^ cells: it was increased in subject exposed to silica, whether considering its relative percentage, according to exposure status (*p* = 0.046, [Figure 2B](#F2){ref-type="fig"}, left panel) and length of exposure (*p* = 0.057, [Figure 2B](#F2){ref-type="fig"}, right panel) or especially considering its total count, according to exposure status and duration (*p* \< 0.0001, [Figure 2C](#F2){ref-type="fig"}). In the latter case, a significantly higher count of HLA-DR^+^CD4^+^ T cells was observed in each subgroup. In CD3^+^CD8^+^ cells, there was a significant increase in HLA-DR expression when comparing total counts according to exposure status (*p* = 0.004, [Figure 2C](#F2){ref-type="fig"}, left panel) or exposure length (*p* = 0.012, [Figure 2C](#F2){ref-type="fig"}, right panel).

Decreased Tregs to Activated T Cells Ratio With Length of CS Exposure
---------------------------------------------------------------------

We used the Tregs to activated T cells ratio to emphasize the relationship between these two subpopulations. The Tregs to activated CD3^+^ T cells ratio, as well as the Tregs to activated CD4^+^ T cells ratio were significantly decreased according to exposure status ([Figure 3](#F3){ref-type="fig"}, left panels) and length of exposure ([Figure 3](#F3){ref-type="fig"}, right panels). Differences were observed for both relative percentages ([Figure 3A](#F3){ref-type="fig"}) and absolute cell counts ([Figure 3B](#F3){ref-type="fig"}) (adjusted *p* \< 0.01 for each analysis). Similar results were observed for Tregs to activated CD4^+^ T cell ratio, while only a trend was observed for Tregs to activated CD8^+^ T cell ratio ([Figure 3](#F3){ref-type="fig"}). Complete data are reported in [Supplemental Table 4](#SM6){ref-type="supplementary-material"}.

![Ratio of Tregs to activated T cells is lower in CS exposed subjects and decreases with length of exposure. Ratio of Tregs to activated T cells was determined as described elsewhere ([@B34]). Ratio of percentages of Tregs to activated T cells in subjects exposed or not to silica (**A**, left) or in subgroups of subjects exposed to silica (**A**, right). Ratio of total count of Tregs to activated T cells in subjects exposed or not to silica (**B**, left) or in subgroups of subjects exposed to silica (**B**, right). Data are shown as boxplot. *P*-values represent Mann & Whitney test for two groups comparison and, Kruskal-Wallis test for four groups comparison (if previous test significant), followed by *post-hoc* Dunn test when applicable (results indicated by asterisks, \*). *P*-values have been adjusted according to Hochberg method to account for repeated analysis. NA, not applicable.](fimmu-10-02743-g0003){#F3}

Higher Frequency of Autoantibodies Detection in CS Exposed Workers
------------------------------------------------------------------

ANA were found in 20/55 (36.4%) workers vs. in 2/45 (4.4%) HC (*p* \< 0.0001; [Figure 4A](#F4){ref-type="fig"}, left panel). Positive ANA was observed more frequently in subjects with longer CS exposure: 30% (3/10), 27.8% (5/18), and 44.4% (12/27) in subjects exposed \<5 years, 5--10 years, and more than 10 years, respectively (*p* = 0.0002; [Figure 4A](#F4){ref-type="fig"}, right panel). When sought (titer over 1/320th), no specificity was found for these ANAs and no anti-DNA antibodies were detected (data not shown). ANA titers are summarized in [Supplemental Figure 2](#SM2){ref-type="supplementary-material"}.

![Higher frequency of autoantibodies levels in CS exposed workers. Percentage of subjects with ANA ≥ 1/200th according to exposure status (**A**, left) or exposure duration (**A**, right). Percentage of subjects with ANCA according to exposure status (**B**, left) or exposure duration (**B**, right).](fimmu-10-02743-g0004){#F4}

ANCA were found in 6/55 subjects (10.9%) exposed to CS vs. in 1/45 HC (2.2%) (*p* = 0.12; [Figure 4B](#F4){ref-type="fig"}, left panel). The 6 ANCA-positive workers were exposed for more than 10 years to CS (6/27; 22.2%) (*p* = 0.01; [Figure 4B](#F4){ref-type="fig"}, right panel). In exposed groups, the IIF pattern was cytoplasmic in 2 subjects (cANCA; titer 1/100th and 1/500th), perinuclear in 2 subjects (pANCA; titer 1/50th and 1/100th) and atypical in 2 subjects (aANCA; titers 1/500th). ANCA positivity was confirmed by ELISA in two subjects (one with a pANCA and one with an aANCA pattern), both exhibiting MPO reactivity. In control group, IIF pattern was cytoplasmic (titer 1/20th) without any identified target in ELISA. ACPA and RF were not detected in exposed workers.

Discussion {#s4}
==========

In this prospective cohort study, we analyzed epidemiological, hematological and immunological data from 55 workers exposed to CS and free from silicosis. Compared to age- and sex- matched HC, we found a significant decrease in the frequency of Tregs and a significant increase in the absolute count of activated HLA-DR^+^ T-cell, associated with length of CS exposition. Moreover, we found a significant increase in ANA and ANCA frequency in CS exposed workers.

In contrast with our initial hypothesis, we did not find a decrease in total lymphocyte count in subject exposed to CS, but rather a slight increase during the first 10 years of CS exposure while remaining within the normal range. We suggest that this slight increase may be related to inflammation due to CS inhalation. Of note, previous studies that reported lymphopenia in silica-exposed workers, with ([@B13]) or without silicosis ([@B35]), enrolled much older subjects (70 ± 3.5 and 59 ± 10 years old, respectively) or much longer exposed workers (20 ± 9 years) ([@B35]). Anyway, we observed a significant decrease in the percentage of Tregs in our population. This could reflect the initial steps to tolerance breakdown, as a decrease in the frequency or number of Tregs has been associated with AID, such as SLE ([@B28], [@B29]), systemic sclerosis ([@B25]--[@B27]) or rheumatoid arthritis ([@B30]--[@B32]). In AAV patients, unlike other AID, an increased proportion of Tregs has rather been reported ([@B36]) but with impaired properties ([@B37]). An imbalance between effector and regulatory T cells has been demonstrated critical in the pathogenesis of these diseases.

This is, to our knowledge, the first study showing a decreased percentage of Tregs in workers exposed to CS free from silicosis and from any other AID. In silicosis patients, two studies showed that Tregs were decreased. However, a limitation in these studies is that Tregs were defined as CD4^+^CD25^+^ cells and FoxP3 expression was not assessed ([@B38], [@B39]). Moreover, when PBMC from HC were cultured with silica, CD4^+^FoxP3^+^ cells was markedly decreased ([@B40]).

In patients with silicosis, different mechanisms have been proposed to explain changes in Tregs/effector T cells balance. First, an increase in Tregs apoptosis has been related to and increased expression of the cell death receptor CD95/Fas molecule ([@B41]), and to anti-Fas antibodies ([@B42]). Second, different signals lead to the activation and proliferation of T helper cell: they express more PD-1 (activation marker) ([@B40]) and Decoy Receptor 3 (DcR3, which prevents Fas-induced apoptosis) ([@B43]). They also produce a soluble form of the CD95, which is anti-apoptotic and release more soluble IL-2 receptor ([@B42], [@B44]). Thus, this imbalance may sustain the effector functions of lymphocytes. Another explanation for Tregs decrease in peripheral blood, is that they may be recruited into secondary lymphoid organs or subclinical damaged organs such as lungs. Indeed, Huaux et al. reported that Tregs were markedly accumulated in the lung and the thymus during the development of silica-induced lung fibrosis in mice ([@B45]).

Secondly, through an increased expression of HLA-DR, we found a more pronounced activation profile in T cells, including total CD3^+^, CD4^+^, and CD8^+^ T cells. The HLA-DR antigen is a cell surface glycoprotein encoded by genes of the major histocompatibility complex. It is constitutively expressed on the surface of antigen presenting cells (monocytes, macrophages, B cells) and is normally absent on resting T cells. However, it can be found at the cell surface of a significant percentage of T cells upon activation. More precisely, it appears at late stages of T cells activation: its expression starts after 24 h of activation and remains high for up to several weeks ([@B46]). It is thus considered as a very late activation marker, allowing to evaluate the global activation status of immune cells. Its expression on T cells was proven to correlate with lupus activity either when analyzed on CD3^+^ T cells ([@B47]), CD4^+^ T cells ([@B22], [@B48]--[@B52]), or CD8^+^ T cells ([@B22], [@B49], [@B51], [@B52]). It was shown that HLA-DR expression on CD3^+^ T cells was higher in lupus patients with anti-DNA antibodies as compared to HC ([@B47]) and was higher on CD8^+^ T cells in patients experiencing a lupus flare ([@B22]). Similar observations were made in patients with rheumatoid arthritis ([@B21], [@B53]), antiphospholipid syndrome ([@B54]) and with rejection in solid organ transplantation ([@B55]).

The increased percentage of activated T cells that we found in subjects exposed to silica could reflect a chronic T cells stimulation by silica particles released from damaged macrophages. Indeed, *in vitro*, silica can have a "superantigen" action on human T cells ([@B33]). In other words, it means that silica can lead to the activation of a T cell by an antigen presenting cell (APC) regardless of its specificity for the presented antigen. Thus, silica particles have an adjuvant effect that can non-specifically enhance the immune response. However, the threshold above which this long-established adjuvant effect appears is not yet fully understood ([@B56]) and remains to be studied.

This activation status observed in subjects exposed to CS is consistent with some previous reports. Indeed, increased levels of circulating soluble IL-2 receptor, released by activated T cells after cleavage of its membrane form, were found in subjects exposed to silica, with ([@B44]) or without silicosis ([@B57]). We also join back our previous data showing an increased HLA-DR expression on total CD3^+^ T cells in silicotic patients ([@B13]). Finally, our results are also congruent with *in vitro* findings: first, the expression of the early expression marker CD69 was increased on lymphocytes when PBMC were cultured with silica ([@B58]); second, it was reported that silica could have a direct effect on T and B cells activation (activation of the TCR-complex and of the BCR-complex indicated by an increased phosphorylation level of the zeta chain and Igα, respectively) and proliferation (indicated by an increased expression of the transcription factor c-Myc), demonstrating that APC are not essential in these pathways and that silica can circumvents many self-tolerance check-points ([@B59]).

The ratio between Tregs and activated T cells, which reflect the imbalance between both subsets ([@B34]), was significantly decreased (especially Tregs to activated CD3^+^ and CD4^+^ T cells) in exposed workers and decreased along with duration of CS exposure. Thus, it may be used to identify patients at risk of tolerance breakdown; however, this needs to be specifically evaluated.

Whether considering Tregs, activated T cells or their ratio, results found in the group with the shortest time of exposure were often close to those found in the control group, and gradually increased (or decreased) with exposure duration. This suggests a coherent cumulative effect of silica exposure duration. This has already been underlined in the cohort of World Trade Center--exposed firefighters and Emergency Medical Service workers ([@B60]). In this cohort, it was demonstrated that every additional month worked in the dusty site increased the occurrence of AID.

At last, we highlighted an increased frequency of auto-antibodies in subjects exposed to CS. ANA and ANCA were particularly more frequent in the subgroup with the longer exposure to CS. ANA and ANCA have been mainly found in ill silica-exposed workers, with silicosis ([@B13], [@B61], [@B62]) or AID alone ([@B10], [@B63]). However, our results are consistent with others studies including asymptomatic exposed subjects ([@B56], [@B62], [@B64], [@B65]). This result is also in accordance with animal data showing an increased production of ANA in lupus-prone NZM mice ([@B66]) and the known adjuvant effect of CS on antibody production ([@B67]). However, it is unclear whether autoantibody production in silica-exposed workers is predictive for the development of further AID. In opposition to some studies, our results and another study ([@B68]) did not detect RF nor ACPA in CS exposed workers. We suggest that these discrepancies may be related to physical particularities of CS microparticles in our cohort.

The major limitation of our study is that we could not identify precisely the duration of exposure, e.g., subjects exposed during 20 years to CS were pooled with those exposed only 11 years in the same subgroups, and, in opposition, subjects exposed only a few months were pooled with those exposed 4 years. This pooling strategy may have underestimated or overestimated some of the differences observed. Another limitation is that we did not follow subjects exposed to CS over time and could not correlate our findings with further occurrence of AID. Lastly, beyond silica exposure on regulatory T cells and T cells activation, many other immune tolerance mechanisms were not investigated. For example, we did not examine HLA alleles, nor did we study the link between potential MHC Class II restrictions and autoantibodies development.

In conclusion, we show that silica exposure is associated with a tolerance breakdown. It is associated with a decrease of Tregs frequency and an increase of T cell activation, and, consequently, an imbalance of Tregs/activated T cells ratio. We hypothesize that this leads to B cell activation leading ultimately to the production of auto-antibodies. These immune dysregulations are already present in non-silicotic CS-exposed subjects. Whether silicosis represent a later stage of these dysregulations or if specific endogenous or exogenous factors lead to silicosis development remain to be studied.

These mechanisms and others previously described, that lead to auto-immunity and tissue damage, are summarized in [Figure 5](#F5){ref-type="fig"}.

![General overview of immune dysregulation induced by silica exposure. This figure summarizes current understanding of silica-induced tolerance breakdown. Phagocytosis of silica particles leads to inflammasome activation ([@B69], [@B70]), production of pro-inflammatory cytokines (IL-1β, TNF-α) ([@B71], [@B72]) and ROS production ([@B71], [@B73], [@B74]). Phagocytic cells capable of antigen presentation (APC) will induce an effector T response amplified by the dysregulation of the effector/regulator T balance and resulting to autoantibodies secretion by B cells. This imbalance is the result, on the one hand, of anti-apoptotic signals (sFas, DcR3) ([@B42], [@B43]) and, on the other hand, pro-apoptotic signals (increased Fas expression, anti-Fas antibodies) ([@B42]). Silica particles are also believed to play a direct role in lymphocyte activation and proliferation. In parallel, cells that have phagocyted silica, unable to destroy it, will not only release it (thus perpetuating the phenomenon) but also will die, releasing DAMPs (in case of necrosis) or responsible of apoptotic debris accumulation, also leading to inappropriate activation of the immune system ([@B75]). Ag, antigen; APC: antigen presenting cell; DAMP: Danger Associated Molecular Pattern; MP; macrophages; PMN, polymorphonuclear; ROS, Reactive Oxygen Species; sFas: soluble Fas; DcR3: Decoy Receptor 3.](fimmu-10-02743-g0005){#F5}
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Flowchart of the study.
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###### 

Antinuclear antibody (ANA) titers. ANA titers according to silica exposure status **(A)** or exposure duration **(B)**. Each dot represents one subject. ND, not detected.
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Antibodies used for flow cytometry analysis.
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Occupation of subjects exposed to silica (*n* = 55).
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###### 

Hematological data. Data are show as Mean ± SD or Median \[interquartile range\]. Statistical tests have been performed sequentially: (1) Mann & Whitney test (otherwise specified), (2) Kruskal-Wallis test (otherwise specified), if previous test significant, (3) Dunn *post-hoc* test, if previous test significant (0 = control group, 1,2,3 = groups exposed \<5, 5--10, \>10 years, respectively). *P*-values have been adjusted according to Hochberg method to account for repeated analysis.
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###### 

Regulatory T cells (Tregs), activated T cells and ratio of Tregs to activated cells, complete data. Data are shown as Median \[Interquartile range\]. Count is in cells/μL. Statistical tests have been performed sequentially: (1) Mann & Whitney test, (2) Kruskal-Wallis test, if previous test significant, (3) Dunn *post-hoc* test, if previous test significant (0 = control group, 1,2,3 = groups exposed \<5, 5--10, \>10 years, respectively). *P*-values have been adjusted according to Hochberg method to account for repeated analysis.
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AAV

:   ANCA Associated Vasculitis

ACPA

:   Anti-Citrullinated Protein Antibody

AID

:   Autoimmune Disease

ANA

:   Antinuclear Antibodies

ANCA

:   Anti-Neutrophil Cytoplasmic Antibodies

ANOVA

:   Analysis of Variance

APC

:   Antigen Presenting Cell

CD

:   Cluster of Differentiation

COPD

:   Chronic obstructive pulmonary disease

CS

:   Crystalline Silica

HLA

:   Human Leucocyte Antigen

IIF

:   Indirect ImmunoFluorescence

IQR

:   Interquartile Range

MEV

:   Mean Exposure Value

PBMC

:   Peripheral Blood Mononuclear Cell

RA

:   Rheumatoid Arthritis

ROS

:   Reactive Oxygen Species

SLE

:   Systemic Lupus Erythematosus

SSc

:   Systemic Sclerosis

Tregs

:   regulatory T cells.
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